A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

  1. Guerra, A.
  2. Costantino, C.
  3. Martinon-Torres, F.
  4. Westerholt, S.
  5. Lambeth, C.
  6. Chen, Z.
  7. Lumley, J.
  8. Marcek, T.
  9. Johnson, D.
  10. Wilck, M.
Journal:
Human Vaccines and Immunotherapeutics

ISSN: 2164-554X,  2164-5515

Year of publication: 2024

Volume: 20

Issue: 1

Type: Article

DOI: 10.1080/21645515.2024.2310900 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus